436 results on '"Hidradenitis Suppurativa surgery"'
Search Results
2. Evaluation of post-surgical complications of hidradenitis suppurativa lesions explored with presurgical ultra-high frequency ultrasound mapping.
- Author
-
Dini V, Michelucci A, Granieri G, Zerbinati N, Margiotta FM, and Romanelli M
- Subjects
- Humans, Retrospective Studies, Male, Female, Adult, Middle Aged, Wound Healing, Preoperative Care, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa diagnostic imaging, Postoperative Complications epidemiology, Ultrasonography
- Abstract
Objective: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Its treatment often requires a surgical approach. The aim of our study was to evaluate the occurrence of post-surgical complications following a new standard of surgical management. This included presurgical lesion mapping by ultra-high frequency ultrasound (UHFUS) with a 70MHz probe. Postoperative management was based on the principles of HS-TIME (time, inflammation/infection, moisture, edges)., Method: A single-centre, retrospective study was conducted by the Department of Dermatology of the University of Pisa. Patients with moderate and severe HS, refractory to previous medical and surgical therapies, were enrolled. All of the patients were treated with wide surgical excision of lesions, previously explored through a UHFUS evaluation with VEVO MD (Fujifilm VisualSonics, Inc., Canada) using a 48MHz and a 70MHz ultrasound probe. Following surgery, all patients were treated with secondary intention healing following the principles of HS-TIME. For each patient, we assessed the occurrence of post-surgical complications at follow-up visit six months after surgery. For each patient we assessed the occurrence of early post-surgical complications at every follow-up visit after surgery until complete wound healing. The occurrence of delayed complications was then assessed in all patients with an observation time after complete healing of >3 months (n=23)., Results: A total of 26 patients were enrolled in the study. There were no reported cases of post-surgical bleeding or haematoma occurrence, while three (11.5%) patients developed minor surgical site infection. The average severity of pain decreased from a numerical rating scale of 5.3 immediately after surgery to 1.3 after four weeks. The average healing time was 33.3±16.8 days, and only five (19.2%) patients reported a complete wound healing time of >6 weeks. Focusing on delayed complications: 1/23 (4.3%) patient had hypertrophic scarring; 2/23 (8.7%) patients reported dysaesthesia; and 2/23 (8.7%) cases of clinical relapse were reported. No cases of limited mobility at the surgery site were registered., Conclusion: The findings of the study demonstrated the efficacy of a novel surgical protocol, including a preoperative ultrasound evaluation and appropriate postoperative wound management. Further prospective studies are needed to validate the observed results; however, we conclude that the low recurrence rates and post-surgical complications confirmed that our proposed protocol would represent an effective strategy for the management of patients with HS eligible for surgical therapy.
- Published
- 2024
- Full Text
- View/download PDF
3. Staged Regional Deroofing for the Treatment of Extensive Hidradenitis Suppurativa.
- Author
-
Suleman S, Riddle AO, and Pena-Robichaux V
- Subjects
- Humans, Male, Adult, Female, Treatment Outcome, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa therapy
- Published
- 2024
- Full Text
- View/download PDF
4. Wound area severity index (WASI): A novel tool for assessing and predicting healing times in hidradenitis suppurativa postsurgical wounds.
- Author
-
Michelucci A, Manzo Margiotta F, Innocenti S, Vietina A, Granieri G, Janowska A, Morganti R, Romanelli M, and Dini V
- Subjects
- Humans, Surgical Wound, Female, Time Factors, Male, Adult, Middle Aged, Hidradenitis Suppurativa surgery, Wound Healing, Severity of Illness Index
- Abstract
Hidradenitis suppurativa (HS) presents challenges in management due to its chronic nature and high risk of recurrence. Post-surgical wound care plays a crucial role in treatment, even if standardized methods for assessing and predicting healing times are lacking. The aim of the study is to introduce the Wound Area Severity Index (WASI) as a novel tool to guide clinicians in assessing postsurgical wound progression and predicting potential healing times. A team of wound healing experts assessed 93 post-surgical HS wounds resulting from wide excision and secondary intention healing. For each wound healing time, wound area, wound bed score (WBS), and WASI were evaluated. WASI includes four parameters: area, temperature, depth and wound Bed, each with four severity levels. The total WASI score ranges from 4 to 16. Spearman correlation and Kruskal-Wallis tests were employed for statistical analysis. WASI strongly correlated with wound healing time (rho: 0.813, p < 0.001). Higher WASI scores were associated with prolonged healing, while lower scores indicated almost healed wounds. The WASI score has proven to be more highly predictive of healing times when compared to the individual parameter of the Area (moderate positive correlation, r: 0.77) and the WBS (negative correlation, r: -0.72). A total WASI score of 4 corresponded to a median healing time of 7 days, while a score exceeding 9 suggested a median healing time of 56 days. WASI has proven to be a valuable tool for assessing and predicting healing times in post-surgical HS wounds. Its simplicity, cost-effectiveness, and ability to integrate multiple parameters make it a promising addition to wound care practice., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Commentary on "Staged Regional Deroofing for the Treatment of Extensive Hidradenitis Suppurativa".
- Author
-
Goldberg SR
- Subjects
- Humans, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa therapy
- Published
- 2024
- Full Text
- View/download PDF
6. No increased risk of postoperative adverse events in patients with hidradenitis suppurativa following a total joint replacement.
- Author
-
Cornman HL, Kambala A, Nandi TR, Kwatra SG, and Nandi S
- Subjects
- Humans, Female, Male, Middle Aged, Risk Factors, Adult, Reoperation statistics & numerical data, Arthroplasty, Replacement adverse effects, Prosthesis-Related Infections etiology, Prosthesis-Related Infections epidemiology, Aged, Surgical Wound Dehiscence etiology, Surgical Wound Dehiscence epidemiology, Patient Readmission statistics & numerical data, Wound Healing, Hidradenitis Suppurativa surgery, Postoperative Complications epidemiology, Postoperative Complications etiology
- Abstract
There is concern for increased risk of adverse events, particularly periprosthetic joint infection (PJI), following total joint replacement (TJR) in patients with hidradenitis suppurativa (HS) because of a compromised skin barrier and bacterial colonization of lesions. We used the TriNetX health research database to identify patients who had undergone TJR with (n = 1760) and without (n = 1760) HS matched by age, sex, ethnicity, race and risk factors for PJI. Multivariate analysis was performed and revealed that 90-day risk of PJI, reoperation, wound dehiscence, delayed wound healing, emergency room visits and readmission were not increased among patients with HS who underwent TJR. Given these findings, dermatologists and orthopaedists should not defer TJR access for patients with HS, as risk of postoperative complications is not prohibitive., Competing Interests: Conflicts of interest S.G.K. is an advisory board member/consultant for AbbVie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. S.N. receives financial or material support from Springer Publishing, is on the editorial or governing board of The Journal of Arthroplasty and is a board member of the American Academy of Orthopaedic Surgeons and American Association of Hip and Knee Surgeons. The other authors declare no conflicts of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
7. Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta-analysis.
- Author
-
Shipman WD 3rd, Williams MN, Suozzi KC, Eisenstein AS, and Dover JS
- Subjects
- Humans, Treatment Outcome, Laser Therapy methods, Lasers, Solid-State therapeutic use, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa therapy, Hair Removal methods
- Abstract
Objectives: Hidradenitis suppurativa (HS) is a chronic inflammatory condition characterized by painful nodules, draining tunnels, and fibrotic scarring in intertriginous, hair-bearing areas. The pathogenesis involves follicular occlusion and subsequent rupture, leading to uncontrolled inflammation. Treatment options for HS are limited and lack universal effectiveness. Laser hair removal (LHR) has been explored as a potential treatment; however, the efficacy and appropriate laser modalities remain unclear. This systematic review examined the efficacy and adverse effects of LHR in HS., Methods: A comprehensive literature search was conducted from inception to September 2023 in Ovid MEDLINE, Ovid Embase, and The Cochrane Library (Wiley) with predefined inclusion and exclusion criteria, and a meta-analysis was conducted., Results: Ten studies were selected (n = 227 total patients) and included six randomized controlled trials, two nonrandomized experimental studies, and two case series. Various laser modalities, including long-pulsed neodymium-doped yttrium aluminum garnet (Nd:YAG) (n = 115), intense pulsed light (n = 18), Alexandrite (n = 54), intralesional 1064 nm diode (n = 20), and combined fractional CO
2 and long-pulsed Nd:YAG laser (n = 20), consistently demonstrated significant improvement in HS disease severity, irrespective of the disease scoring method used. Minimal adverse effects (primarily mild pain and erythema) were reported. A meta-analysis of three studies utilizing long-pulsed Nd:YAG laser demonstrated a standardized mean difference in disease severity of -1.68 (95% confidence interval: -2.99; -0.37), favoring treatment with LHR for HS., Conclusions: Hair follicles are key in HS pathogenesis and all included studies showed a significant improvement in HS disease severity after LHR regardless of the laser device used, likely related to hair follicle unit destruction. HS is a complex and heterogenous condition, and multiple disease scoring methods complicate outcome comparisons across studies. However, LHR, utilizing various techniques, is an effective treatment option for HS with minimal adverse effects., (© 2024 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
8. Bariatric surgery reduces the incidence of hidradenitis suppurativa in individuals with obesity: results of a nationwide administrative data study in France.
- Author
-
Chierici A, Bulsei J, Alromayan M, Alamri A, Pavone G, Fontas E, and Iannelli A
- Subjects
- Humans, France epidemiology, Female, Male, Adult, Incidence, Case-Control Studies, Middle Aged, Databases, Factual, Recurrence, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa complications, Bariatric Surgery, Obesity complications, Obesity epidemiology, Obesity surgery
- Abstract
Background: Hidradenitis suppurativa (HS) is a systemic inflammatory condition associated with obesity, metabolic syndrome, and environmental factors. Bariatric surgery (BS) is effective in reducing weight and resolving obesity-related medical problems., Objectives: The aim of this case-control study is to evaluate the effects of BS on the occurrence and recurrence of HS in individuals with obesity., Setting: Nationwide administrative data study using the French national discharge database., Methods: We compared 297,776 individuals with obesity and without a history of HS who underwent BS (BS group) with 2,735,930 individuals with obesity who did not receive BS (control group) to assess the incidence of de novo HS. From the same database, we compared hospitalization rates for HS recurrence between 310 individuals with obesity and HS who had BS (HS_BS group) and 3875 individuals with obesity who did not have BS (HS_control group). Propensity score matching using the nearest-neighbor method was implemented to create comparable patient groups., Results: Individuals with obesity and without a history of HS who received BS exhibited a significantly reduced risk of developing de novo HS (RR = .736 [.639; .847]). Among patients with a history of HS, those who underwent BS had a nonsignificantly reduced risk of HS recurrence (RR = .676 [.369; 1.238]) compared with those who did not., Conclusion: BS reduces the risk of developing de novo HS and seems to have a protective effect on its recurrence in individuals with obesity, although the latter effect was not statistically significant., (Copyright © 2024 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Modified PECS II Block for Axillary Hidradenitis Suppurativa.
- Author
-
Shalaby M, Sahni R, Puebla D, and Fernandez S
- Subjects
- Humans, Female, Adult, Emergency Service, Hospital, Drainage methods, Hidradenitis Suppurativa complications, Hidradenitis Suppurativa surgery, Nerve Block methods, Axilla, Anesthetics, Local administration & dosage, Anesthetics, Local therapeutic use
- Abstract
Background: Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin condition. Patients experience exacerbations, leading them to present to the emergency department (ED) for incision and drainage. Direct injection of local anesthetic into these lesions is extremely painful and seldom provides adequate anesthesia. A modified method of the PECS II block can provide anesthesia to the skin of the axilla, making management of HS much less painful for the patient. We performed a bilateral modified PECS II block on a patient requiring incision and drainage of HS lesions in both axillae. She subsequently required no local anesthetic for the procedure., Discussion: The second injection of the traditional PECS II block involves the deposition of anesthetic in the fascial plane between the pectoralis minor muscle and the serratus anterior muscles. This injection targets the lateral branch of the intercostal nerves, which provide sensory innervation to the axilla., Conclusions: A modified technique of the PECS II block, in which only the second injection is performed, is a potentially effective method for anesthetizing the axilla of patients with HS prior to incision and drainage., Competing Interests: Declaration of competing interest None., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Punch debridement (mini-deroofing): An in-office surgical option for hidradenitis suppurativa.
- Author
-
Mansour MR, Rehman RA, and Daveluy S
- Subjects
- Humans, Ambulatory Surgical Procedures methods, Male, Female, Adult, Hidradenitis Suppurativa surgery, Debridement methods, Debridement instrumentation
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
11. Management of Pilonidal Disease and Hidradenitis Suppurativa.
- Author
-
Singh S, Desai K, and Gillern S
- Subjects
- Humans, Hair Removal methods, Hidradenitis Suppurativa therapy, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa complications, Hidradenitis Suppurativa diagnosis, Pilonidal Sinus surgery, Pilonidal Sinus therapy, Pilonidal Sinus diagnosis
- Abstract
Pilonidal disease and hidradenitis suppurativa affect healthy young adults, causing discomfort and pain that leads to loss of work productivity and should be approached in a personalized manner. Patients with pilonidal disease should engage in hair removal to the sacrococcygeal region and surgical options considered. Hidradenitis suppurativa can be a morbid and challenging disease process. Medical management with topical agents, antibiotics, and biologics should be used initially but wide local excision should be considered in severe or refractory cases of the disease., Competing Interests: Disclosures Authors have nothing to disclose., (Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
12. [Translated article] Use of Loop Diathermy Conization for Deroofing Fistulotomy in Hidradenitis Suppurativa: A Rapid, Simple, and Versatile Technique.
- Author
-
Mansilla-Polo M, Canet-Plana M, and Morgado-Carrasco D
- Subjects
- Humans, Conization methods, Diathermy methods, Time Factors, Cutaneous Fistula etiology, Cutaneous Fistula surgery, Female, Hidradenitis Suppurativa surgery
- Published
- 2024
- Full Text
- View/download PDF
13. Is there a surgical window of opportunity in hidradenitis suppurativa?
- Author
-
Muñoz-Barba D, Sánchez Díaz M, Montero Vílchez T, Molina Leyva A, and Arias Santiago S
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Hidradenitis Suppurativa surgery
- Published
- 2024
- Full Text
- View/download PDF
14. Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review.
- Author
-
Nilforoushzadeh MA, Heidari N, Heidari A, Ghane Y, Hosseini S, Lotfi Z, Jaffary F, Nobari MN, Aghamiri ZS, and Nobari NN
- Subjects
- Humans, Treatment Outcome, Quality of Life, Hidradenitis Suppurativa radiotherapy, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa therapy, Radiofrequency Therapy methods
- Abstract
Background and Aims: Hidradenitis suppurativa (HS) is an inflammatory skin disease affecting apocrine gland-bearing sites of the body. Radiofrequency (RF) is a minimally invasive method that acts by minimizing thermal damage to the dermis, resulting in collagen synthesis and scar improvement. We systematically reviewed the efficacy and safety of RF in treating HS., Methods: A systematic search was performed up to November 18th, 2023, in PubMed/Medline, Ovid Embase, and Web of Science. Clinical studies with English full texts were included. The National Institute of Health (NIH) Quality Assessment Tool for clinical trials and Methodological quality and synthesis of case series and case reports by Murad et al. were utilized for critical appraisal., Results: Out of 55 identified studies, 11 met our inclusion criteria with 167 subjects who underwent RF therapy alone or combined with an intense pulsed laser (IPL), known as LAight®. LAight® significantly improved clinical outcomes in mild-to-moderate HS patients based on the Dermatology Life Quality Index (DLQI), International Hidradenitis Suppurativa Score System (IHS4), Pain-Numerical Rating Scale (NRS), and Hidradenitis Suppurativa Clinical Response (HiSCR). Moreover, RF therapy alone significantly alleviated the clinical manifestations in patients with mild-to-moderate HS. Additionally, fractional microneedling RF significantly decreased HS-associated inflammatory markers. RF was found to be safe with limited adverse events. However, in moderate-to-severe HS, RF has failed to yield satisfactory results., Conclusion: RF is a safe energy-based method with promising outcomes, especially for long-term application in mild-to-moderate HS. In moderate-to-severe cases, RF should be combined with a systemic medication for further beneficial impacts., (© 2024. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
15. A review of surgical and reconstructive techniques for hidradenitis suppurativa.
- Author
-
Wong HS, Jiang JY, Huang SD, Zhu P, Ji X, and Wang DG
- Subjects
- Humans, Axilla surgery, Buttocks surgery, Dermatologic Surgical Procedures methods, Surgical Flaps transplantation, Treatment Outcome, Hidradenitis Suppurativa surgery, Plastic Surgery Procedures methods
- Abstract
Hidradenitis suppurativa (HS) is an inflammatory follicular dermatological condition that typically affects the intertriginous and anogenital regions of the apocrine gland-bearing skin. The management of this chronic and recurring disease necessitates a combination of lifestyle changes, medication, and surgical approaches to achieve the best possible outcomes. While medical treatments are recommended for this multimodal disease, surgical therapy, which is the gold standard of treatment for HS, has proven to be the most effective treatment because it provides long-lasting local disease control, reduces the recurrence of lesions, and ensures complete healing of lesions. In the last decade, there has been exponential growth in research into various surgical techniques and reconstructive care, enabling patients to have more surgical options. There is a wide range of surgical management procedures available, such as incision and drainage, deroofing, excisional surgery, carbon dioxide laser therapy, and skin tissue-sparing excision with electrosurgical peeling. Among these surgical procedures, wide surgical excision is the best option since it can eradicate all the affected lesions. Meanwhile, the preferred approach to reconstruction at various anatomical locations remains debatable. Here, we review a variety of surgical treatments and reconstructive techniques for HS, particularly various flap techniques for the axillary, gluteal, and inframammary regions., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
16. Deroofing: A safe, effective and well-tolerated procedure in patients with hidradenitis suppurativa.
- Author
-
Krajewski PK, Sanz-Motilva V, Flores Martinez S, Solera M, Ochando G, Jfri A, and Martorell A
- Subjects
- Humans, Male, Female, Adult, Prospective Studies, Middle Aged, Young Adult, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa complications, Patient Satisfaction
- Abstract
Introduction: Hidradenitis suppurativa (HS) is a recurrent, debilitating, chronic disorder of the pilosebaceous unit. Although advances in HS treatment have been made, more than 45% of patients remain dissatisfied with systemic treatment, and more than one-third are dissatisfied with surgical procedures., Objectives: A prospective, observational study on the deroofing procedures in HS with special attention paid to patient satisfaction and complications., Methods: HS lesions were assessed clinically and by the use of ultrasound. Patients reported outcomes, including pain, itch and satisfaction, were measured at 24 h post-surgery by a numeric rating scale (NRS) ranging from 0 to 10. Additionally, the timeline of objective wound closure reported by patients in (weeks), in addition to the need for any analgesics use, were both evaluated., Results: The mean closure time of the post-deroofing wound was assessed as 4.4 ± 1.9 weeks. A statistically longer time was necessary for complete closure in males than in females (4.9 ± 2.2 weeks and 3.9 ± 1.6 weeks, respectively; p = 0.046). The closure time correlated positively yet weakly with the HS tunnel's width (r = 0.27, p = 0.016) and length (r = 0.228, p = 0.044). Patients assessed mean pain at 24 h post-op as mild with 0.7 ± 1.2 points according to NRS, with no differences between sexes. Similarly, itch in the first 24 h was assessed as mild with 1.8 ± 1.1 points, without differences between sexes. No pain, itch or adverse events were reported after 1 week following deroofing. Moreover, no cases of wound infection were reported. An overall patient satisfaction was assessed as 9.9 ± 0.4 points (range 9-10 points)., Conclusion: Deroofing is an easy, effective and safe dermatosurgical procedure that does not require surgical experience or operating theatre. It is associated with no complications and very low post-op pain and should be part of holistic HS management., (© 2024 European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
17. Drainage setons for the management of sinus tracts in hidradenitis suppurativa.
- Author
-
Vilarrasa E, Camiña-Conforto G, Cabo F, Fernández-Vela J, Pousa M, and Romaní J
- Subjects
- Humans, Inflammation, Drainage, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
18. The use of adalimumab to overcome delayed wound healing after wide excision for hidradenitis suppurativa.
- Author
-
Chastagner M, Guillem P, Jullien D, Danset M, and Villani AP
- Subjects
- Humans, Anti-Inflammatory Agents therapeutic use, Adult, Female, Male, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa surgery, Adalimumab therapeutic use, Wound Healing drug effects
- Published
- 2024
- Full Text
- View/download PDF
19. Effects of bariatric surgery on severe suppurative hidradenitis: Results of a nationwide administrative data study in France.
- Author
-
Chierici A, Bulsei J, De Fatico S, Alromayan M, Alamri A, Pavone G, Liddo G, Fontas E, and Iannelli A
- Subjects
- Humans, France, Hidradenitis Suppurativa surgery, Bariatric Surgery methods, Obesity, Morbid complications, Obesity, Morbid surgery
- Published
- 2024
- Full Text
- View/download PDF
20. Insurance coverage among the largest insurers per state for laser hair removal in the treatment of hidradenitis suppurativa.
- Author
-
Ly S, Manjaly P, Kamal K, Theodosakis N, Charrow A, and Mostaghimi A
- Subjects
- Humans, Insurance Carriers, Insurance Coverage, Lasers, Hidradenitis Suppurativa surgery, Hair Removal
- Abstract
Competing Interests: Conflicts of interest Dr Mostaghimi has received consulting or royalty fees from Pfizer, hims, Digital Diagnostics, Concert, Lilly, AbbVie, Equillium, Boehringer Ingelheim, LEO, and ACOM. Dr Charrow has received consulting fees from Novartis. Authors Ly, Manjaly, and Kamal and Dr Theodosakis have no conflicts of interest to declare.
- Published
- 2024
- Full Text
- View/download PDF
21. Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study.
- Author
-
Malvaso D, Chiricozzi A, Fossati B, Antonelli F, and Peris K
- Subjects
- Humans, Male, Retrospective Studies, Female, Adult, Combined Modality Therapy, Recurrence, Postoperative Complications epidemiology, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents adverse effects, Treatment Outcome, Young Adult, Biological Products therapeutic use, Biological Products adverse effects, Middle Aged, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa drug therapy
- Abstract
Background: Hidradenitis suppurativa (HS) is a debilitating chronic skin disease; its therapeutic approach often requires combined medical and surgical treatment., Methods: The aim of this study was to assess the efficacy and safety of the surgical approach combined with different pharmacological treatments, evaluating the proportion of patients achieving the hidradenitis suppurativa clinical response (HiSCR), along with the incidence of postoperative complications, and local recurrence. A retrospective study of HS patients (Hurley I-III) presenting at least one skin lesion requiring surgery was performed. Demographic and clinical data were collected (kind and anatomical location of lesion excised, type of surgical procedure). Further data included: Hurley stage and IHS4 at baseline and week 16, HiSCR at week 16 after surgery, ongoing therapy at the time of surgery (topical, systemic antibiotic, biologics), postoperative complications and local recurrence at week 16., Results: Forty-two patients with female predominance (66.7%, 28/42), with a mean age of 30.3 (SD±10.5) years, were enrolled. At week 16, 53% of patients achieved HiSCR, with baseline Hurley III inversely related to HiSCR achievement (P<0.05). No increased incidence of postoperative complications was detected. Three cases of local recurrence were reported at week 16., Conclusions: The results support the efficacy and safety of the combined therapy in the management of HS; no increased risk of complications emerged among patients concomitantly treated with biologics, compared to those on conventional systemic therapy or exclusively treated with surgery.
- Published
- 2024
- Full Text
- View/download PDF
22. Management of hidradenitis suppurativa tunnels using drainage setons: A retrospective multicentric study.
- Author
-
Fernández-Vela J, Romaní J, Cabo F, Pousa M, Camiña G, Guilabert A, and Vilarrasa E
- Subjects
- Humans, Retrospective Studies, Drainage, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
23. An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa.
- Author
-
Miller A, Shahzeidi P, and Bernhardt M
- Subjects
- Humans, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa surgery, Dermatitis complications
- Abstract
Hidradenitis suppurativa (HS) is a severe, debilitating, chronic inflammatory skin disease characterized by recurrent painful nodules, abscesses and draining sinus tracts in intertriginous areas. While this condition appears to stem from follicular unit dysfunction, its cause is multifactorial and the exact pathogenesis has yet to be fully elucidated. These factors make treatment selection challenging and contribute to variable therapeutic response among affected patients. Typical regimens consist of a combination of medical and surgical modalities, tailored to individual responses. However, HS is often refractory to traditional treatments, prompting the need for newer and more effective therapies. Herein, we review current and emerging HS therapies., Competing Interests: The authors have no conflicts of interest to declare.
- Published
- 2024
24. A simple video demonstrating the deroofing technique for hidradenitis suppurativa.
- Author
-
Hengy M and Daveluy S
- Subjects
- Humans, Wound Healing, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
25. Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study.
- Author
-
Ingram JR, Bates J, Cannings-John R, Collier F, Evans J, Gibbons A, Harris C, Howells L, Hood K, Howes R, Leighton P, Riaz M, Rodrigues J, Stanton H, Thomas KS, and Thomas-Jones E
- Subjects
- Female, Humans, Adult, Male, Rifampin, Doxycycline therapeutic use, Cohort Studies, Clindamycin therapeutic use, Hidradenitis Suppurativa surgery
- Abstract
Background: Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but are rarely offered in the UK., Objectives: To describe current UK HS management pathways and influencing factors to inform the design of future randomized controlled trials (RCTs)., Methods: THESEUS was a nonrandomized 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200 mg daily; oral clindamycin and rifampicin both 300 mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing; and conventional surgery. The primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. The secondary outcomes were the proportion of participants selecting each intervention as their final treatment option; the proportion who switch treatments; treatment fidelity; and attrition rates. THESEUS was prospectively registered on the ISRCTN registry: ISRCTN69985145., Results: The recruitment target of 150 participants was met after 18 months, in July 2021, with two pauses due to the COVID-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36 years, 81% female, 20% non-White, 64% current or ex-smokers, 86% body mass index ≥ 25, 68% with moderate disease, 19% with severe disease and 13% with mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after 3 and 6 months, respectively. Concordance with doxycycline was 52% after 3 months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing, respectively, after 3 months. Uptake of conventional surgery was too small to characterize the intervention. Switching treatment was uncommon and there were no serious adverse events., Conclusions: THESEUS has established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs., Competing Interests: Conflicts of interest J.R.I. receives a stipend as Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. He is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis and UCB Pharma and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for hidradenitis suppurativa (HS). His department receives income from the copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. R.C.-J. was a UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Associate Board Member (May 2018 to March 2020). F.C. is a consultant for UCB Pharma and received a fee from Daylong for participating in a HS consensus meeting. L.H. has received consultancy fees from the University of Oxford for an educational grant funded by Pfizer, unrelated to the submitted work. K.H. is a member of the NIHR HTA General Committee (2016–2022), the NIHR HTA Funding Committee Policy Group (2017–2022) and the NIHR Research Professors Panel (2019–present)., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists.)
- Published
- 2024
- Full Text
- View/download PDF
26. Complex decongestive therapy in hidradenitis suppurativa-related genital lymphoedema: a case report.
- Author
-
Yaman A, Borman P, Eşme P, and Çalışkan E
- Subjects
- Humans, Male, Middle Aged, Antibodies, Monoclonal, Humanized, Genitalia, Hidradenitis Suppurativa therapy, Hidradenitis Suppurativa surgery, Lymphedema therapy, Lymphedema surgery
- Abstract
Genital lymphoedema is a rare but debilitating and disfiguring complication of longstanding hidradenitis suppurativa (HS). Despite the existence of medical and surgical methods that offer varying success rates in a limited number of cases, no data exist about the use of complex decongestive therapy (CDT) in HS-related genital lymphoedema. This case report describes the treatment and outcome of a 56-year-old male patient with severe scrotal lymphoedema due to underlying HS (Hurley stage 3). The patient was unresponsive to various topical and systemic antibiotics and biological agents, including adalimumab and certolizumab pegol. When the patient was assessed, ixekizumab treatment for his HS was planned. He had progressive oedema in the genital area for two years with difficulty in wearing trousers and having sexual intercourse, and painful urination. CDT was recommended for three days a week concurrently with ixekizumab treatment. The patient and his wife were also educated about self-drainage techniques and skincare maintenance. After six sessions of CDT over 14 days, the patient demonstrated a significant reduction in scrotal measurements. He achieved a better scrotal contour, the degree of the buried penis was decreased, and urination was easier and painless. The findings of this case report showed that CDT was an easily applicable, practical and promising method that offered a rapid treatment response for HS-related genital lymphoedema.
- Published
- 2024
- Full Text
- View/download PDF
27. The treatment of perianal hidradenitis suppurativa complicated with complex anal fistula by loose combined cutting seton surgery: A case letter.
- Author
-
Bi W, Fu H, Huang Y, Zeng X, Li X, Guo Y, and Wu T
- Subjects
- Humans, Perineum, Treatment Outcome, Retrospective Studies, Anal Canal, Hidradenitis Suppurativa complications, Hidradenitis Suppurativa surgery, Rectal Fistula complications, Rectal Fistula surgery
- Published
- 2024
- Full Text
- View/download PDF
28. Pedicled circumflex scapular artery perforator flap with intra-axillary tunneling for axillary defect coverage after surgical excision of hidradenitis suppurativa: A case report and literature review.
- Author
-
Meroni M and Scaglioni MF
- Subjects
- Humans, Axilla surgery, Arteries surgery, Perforator Flap blood supply, Hidradenitis Suppurativa surgery, Plastic Surgery Procedures
- Abstract
Axillary defects represent a rather common issue in plastic surgery practice. Surgical resections related to skin disease are frequent in this region and their extension often requires soft tissue transfer for coverage. In this setting, locoregional pedicled flaps are usually preferred. The nearby tissues offer pliable but still resistant skin, which satisfy the "like-with-like" reconstructive principle. Over the years different procedures have been described for this purpose. Among them, a valuable and often underestimated technique is the circumflex scapular artery perforator flap (CSAP). This technique might be particularly suitable for thin but relatively large defects. Its main advantages are a low donor site morbidity, a very reliable anatomy, and a perforator pedicle able supply a large skin paddle. In the present work, we report the use of a pedicled vertical CSAP flap passed through the axillary canal in order to cover a 9 cm × 7 cm axillary defect after surgical excision of hidradenitis suppurativa resistant to conservative treatment. The perforator-based pedicled presented two branches, which allowed us to harvest safely a large skin paddle, which limited its range of motion. For this reason, we opted for a passage through the axillary canal for the flap inset. The postoperative course was uneventful and full shoulder range of motion was obtained at 3 months follow-up. Despite most of the descriptions of this flap available so far showed its employment for limb's reconstructions, we believe that it is a very useful tool also for locoregional coverage. Moreover, the unconventional passage below the axillary muscles allowed reaching the recipient site even with a shorter pedicle, such as the one encountered in this case., (© 2023 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
29. Surgical management of seasonal flares in hidradenitis suppurativa.
- Author
-
Tripathi R and Ezaldein HH
- Subjects
- Humans, Seasons, Severity of Illness Index, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2024
- Full Text
- View/download PDF
30. Use of superficial circumflex iliac artery perforator flap for soft tissues and lymphatic genital reconstruction after hidradenitis suppurativa resection.
- Author
-
Brunetti B, Camilloni C, Putti A, Petrucci V, Pazzaglia M, Papalia R, and Persichetti P
- Subjects
- Humans, Iliac Artery surgery, Genitalia surgery, Perforator Flap blood supply, Hidradenitis Suppurativa surgery, Plastic Surgery Procedures
- Abstract
Competing Interests: Declaration of Competing Interest None declared.
- Published
- 2024
- Full Text
- View/download PDF
31. Use of multiple fasciocutaneous flaps for the management of extensive hidradenitis suppurativa.
- Author
-
Alshammary RH, Hbib Allaha EH, Fakhruddin MS, and Bakhiet M
- Subjects
- Male, Humans, Quality of Life, Surgical Flaps surgery, Skin pathology, Hidradenitis Suppurativa complications, Hidradenitis Suppurativa surgery, Plastic Surgery Procedures
- Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a relapsing nature that has a significant impact on the patient's quality of life. The clinical presentation of the disease includes deep dermal abscesses and sinus tracts. Long-term affliction of the disease may lead to contractures, scars and fibrosis. Management is still challenging and varies from medical to surgical options. We report the following case of a man in his 30s who presented with severe HS in the axillae, groins, perineum and lower sacral region. The patient has been treated by excision of the whole lesions followed by using multiple fasciocutaneous flaps as a reconstructive method., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
32. A Retrospective Review of Laser Therapy for Treatment of Hidradenitis Suppurativa.
- Author
-
Fortoul MC, Macias Martinez B, Ventura Rodriguez D, Dallara M, Stelnicki EJ, and Kamel G
- Subjects
- Humans, Retrospective Studies, Quality of Life, Severity of Illness Index, Hidradenitis Suppurativa surgery, Laser Therapy, Low-Level Light Therapy adverse effects
- Abstract
Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by painful and foul-smelling cystic nodules and sinus tracts in the apocrine gland-bearing regions. The treatment options include topical, intralesional, systemic, and surgical modalities. Currently, the most novel therapy is laser therapy to provide localized treatment without systemic adverse effects. However, data regarding patient outcomes after laser treatment are limited because of the low prevalence of this disease. This study aimed to evaluate the efficacy of laser therapy as a treatment modality for patients with HS., Methods: A retrospective review cohort analysis of patients with HS undergoing laser treatment between 2016 and 2021 was conducted. Patient demographics, lesion location(s), Hurley stage, age of onset and diagnosis, treatment length, type, outcomes, and complications were analyzed., Results: Ninety-four patients met the inclusion criteria; on average, patients were treated with 5.8 laser sessions for 14.8 months with no complications and minor blood loss. Hidradenitis suppurativa progression commonly starts during puberty, with a median onset of 13.8 years and diagnosis of HS at 16.2 years. All patients (n = 94) showed an improvement in HS disease severity: 59.6% completed treatment, 12.0% are currently undergoing treatment, and 26.0% were lost to follow-up., Conclusions: Laser therapy is an effective and safe therapy for HS leading to improved quality of life and should be considered in the treatment and management of HS., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. What should a surgeon know about hidradenitis suppurativa?
- Author
-
Ezanno AC, Guillem P, Gorin C, Gabison G, Malgras B, and Fougerousse AC
- Subjects
- Humans, Abscess diagnosis, Abscess etiology, Abscess surgery, Hidradenitis Suppurativa diagnosis, Hidradenitis Suppurativa surgery, Surgeons
- Abstract
Otherwise known as Verneuil's disease, hidradenitis suppurative (HS) is a severe dermatosis of heterogeneous appearance affecting 1% of the population. Its pathophysiology is multifactorial, involving genetic predisposition, inflammatory disorder and environmental elements. Its diagnosis is based on the association of three clinical characteristics: characteristic lesions, typical localizations, and the chronic and recurrent nature of the lesions. Given its diversified aspects, diagnosis can be difficult to achieve. As its manifestations often include abscesses, it is important for the surgeon to know how to detect this pathology. The development of biologics has improved treatment of this disease, treatment that necessitates a multidisciplinary medical and surgical approach involving dermatologists and proctologists as well as surgeons. The objective of this report is to synthesize what a surgeon will need to know so as effectively treat HS patients., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study.
- Author
-
Ingram JR, Bates J, Cannings-John R, Collier F, Gibbons A, Harris C, Hood K, Howells L, Howes R, Leighton P, Riaz M, Rodrigues J, Stanton H, Thomas KS, and Thomas-Jones E
- Subjects
- Adult, Humans, Female, Male, Clindamycin, Prospective Studies, Rifampin therapeutic use, Cohort Studies, Pandemics, Cost-Benefit Analysis, Randomized Controlled Trials as Topic, Doxycycline therapeutic use, Hidradenitis Suppurativa surgery
- Abstract
Background: Hidradenitis suppurativa is a chronic inflammatory skin disease characterised by recurrent inflammatory lesions and skin tunnels in flexural sites such as the axilla. Deroofing of skin tunnels and laser treatment are standard hidradenitis suppurativa interventions in some countries but not yet introduced in the United Kingdom., Objective: To understand current hidradenitis suppurativa management pathways and what influences treatment choices to inform the design of future randomised controlled trials., Design: Prospective 12-month observational cohort study, including five treatment options, with nested qualitative interviews and an end-of-study consensus workshop., Setting: Ten United Kingdom hospitals with recruitment led by dermatology and plastic surgery departments., Participants: Adults with active hidradenitis suppurativa of any severity not adequately controlled by current treatment., Interventions: Oral doxycycline 200 mg once daily; oral clindamycin and rifampicin, both 300 mg twice daily for 10 weeks initially; laser treatment targeting the hair follicle (neodymium-doped yttrium aluminium garnet or alexandrite); deroofing; and conventional surgery., Main Outcome Measures: Primary outcome was the proportion of participants who are eligible, and hypothetically willing, to use the different treatment options. Secondary outcomes included proportion of participants choosing each of the study interventions, with reasons for their choices; proportion of participants who switched treatments; treatment fidelity; loss to follow-up rates over 12 months; and efficacy outcome estimates to inform outcome measure instrument responsiveness., Results: Between February 2020 and July 2021, 151 participants were recruited, with two pauses due to the COVID-19 pandemic. Follow-up rates were 89% and 83% after 3 and 6 months, decreasing to 70% and 44% at 9 and 12 months, respectively, because pandemic recruitment delays prevented all participants reaching their final review. Baseline demographics included an average age of 36 years, 81% female, 20% black, Asian or Caribbean, 64% current or ex-smokers and 86% with a raised body mass index. Some 69% had moderate disease, 19% severe disease and 13% mild disease. Regarding the study's primary outcome, laser treatment was the intervention with the highest proportion (69%) of participants who were eligible and hypothetically willing to receive treatment, followed by deroofing (58%), conventional surgery (54%), the combination of oral clindamycin and rifampicin (44%) and doxycycline (37%). Considering participant willingness in isolation, laser was ranked first choice by the greatest proportion (41%) of participants. The cohort study and qualitative study demonstrated that participant willingness to receive treatment was strongly influenced by their clinician. Fidelity to oral doxycycline was only 52% after 3 months due to lack of effectiveness, participant preference and adverse effects. Delays receiving procedural interventions were common, with only 43% and 26% of participants commencing laser therapy and deroofing, respectively, after 3 months. Treatment switching was uncommon and there were no serious adverse events. Daily pain score text messages were initiated in 110 participants. Daily responses reduced over time with greatest concordance during the first 14 days., Limitations: It was not possible to characterise conventional surgery due to a low number of participants., Conclusion: The Treatment of Hidradenitis Suppurativa Evaluation Study established deroofing and laser treatment for hidradenitis suppurativa in the United Kingdom and developed a network of 10 sites for subsequent hidradenitis suppurativa randomised controlled trials., Future Work: The consensus workshop prioritised laser treatment and deroofing as interventions for future randomised controlled trials, in some cases combined with drug treatment., Trial Registration: This trial is registered as ISRCTN69985145., Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 12/35/64) and is published in full in Health Technology Assessment ; Vol. 27, No. 30. See the NIHR Funding and Awards website for further award information.
- Published
- 2023
- Full Text
- View/download PDF
35. Evaluating the efficacy of continuous wave carbon dioxide laser therapy in conjunction with biologics for the management of hidradenitis suppurativa.
- Author
-
Maghfour J, Dzuali F, Ezekwe N, Gordon J, and Hamzavi IH
- Subjects
- Humans, Hidradenitis Suppurativa surgery, Biological Products, Lasers, Gas therapeutic use, Laser Therapy
- Abstract
Competing Interests: Conflicts of interest I.H.H. is an investigator for the Patient-Centered Outcomes Research Institute, Incyte Corporation, L’Oréal, Beiersdorf, Estée Lauder, Unigen Inc., Ferndale Healthcare Inc., Pfizer, Allergan and Johnson & Johnson, and has served as a consultant for Pfizer, Johnson & Johnson and Beiersdorf.
- Published
- 2023
- Full Text
- View/download PDF
36. Factors influencing patient experience during incision and drainage procedures in hidradenitis suppurativa: an analysis of patient-reported outcomes.
- Author
-
Revankar RR, Blum F, Yeung H, Patel HA, Holahan H, Vedak P, and Sayed CJ
- Subjects
- Humans, Drainage methods, Patient Reported Outcome Measures, Hidradenitis Suppurativa surgery, Surgical Wound
- Abstract
Competing Interests: Conflicts of interest C.J.S. reports receiving investigator fees from Incyte, AbbVie, Novartis, UCB, ChemoCentryx and InflaRx paid to his institution; receiving consulting fees from UCB and InflaRx paid to his institution and personal consulting fees from Sonoma Biotherapeutics, Alumis, AbbVie, Incyte and Novartis; receiving grants from AbbVie paid to his institution; and receiving personal fees for speaking for AbbVie and Novartis outside the submitted work. The other authors report no conflicts of interest.
- Published
- 2023
- Full Text
- View/download PDF
37. Advances in surgical treatment of hidradenitis suppurative.
- Author
-
Wang Y, Han C, and Wang X
- Subjects
- Humans, Drainage, Postoperative Complications, Skin, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa complications, Hidradenitis complications
- Abstract
Hidradenitis suppurative is a chronic, refractory and recurrent dermatological disease. The disease should be managed by targeted surgical intervention on the basis of medical treatment. Currently, the surgical treatment methods include local treatments like incision and drainage, unroofing, laser therapy, intense pulsed light therapy, photodynamic therapy, as well as complete lesion resection such as skin-tissue saving excision with electrosurgical peeling and extended excision. The clearance range, therapeutic effect, postoperative complications, and recurrence risk vary among the different treatment methods. Local treatments cause less damage, but have high recurrence rates, and are mainly for mild to moderate hidradenitis suppurative patients. Complete lesion resections have relatively low recurrence rates, but may bring more surgical injuries, and postoperative reconstructions are needed, which are mainly for moderate to severe hidradenitis suppurative patients. In this article, the surgical treatment principles and various surgical treatment methods of hidradenitis suppurative are reviewed, to provide a reference for the diagnosis and treatment of this disease in clinical practice.
- Published
- 2023
- Full Text
- View/download PDF
38. The Thoracodorsal Artery Perforator Flap for the Treatment of Hidradenitis Suppurativa of the Axilla: A Prospective Comparative Study.
- Author
-
La Padula S, Pensato R, Pizza C, D'Andrea F, Roccaro G, Meningaud JP, and Hersant B
- Subjects
- Humans, Axilla surgery, Prospective Studies, Quality of Life, Arteries surgery, Pain, Perforator Flap blood supply, Hidradenitis Suppurativa surgery
- Abstract
Background: Hidradenitis suppurativa (HS) is a common chronic condition that is often resistant to conservative treatment and requires a wide and aggressive surgical approach to prevent recurrence. A prospective study was performed comparing the outcomes of thoracodorsal artery perforator (TDAP) flap-based reconstruction and secondary intention closure (SIC) after wide local excision (WLE) of axillary HS., Methods: A prospective study was conducted on 68 patients with stage 3 axillary HS. Thirty-three patients underwent a WLE procedure and were left to heal by secondary intention (SIC group), and 35 patients underwent immediate reconstruction with a homolateral TDAP flap (TDAP group). Inpatient stay, healing time, postoperative complications rate, and pain were analyzed in both groups, comparing preoperative shoulder function (using Constant-Murley shoulder outcome score) and quality of life (using a dermatology life quality index) with postoperative shoulder function and quality of life., Results: Patients receiving TDAP flaps had significantly faster recovery, fewer complications, and fewer overall number of procedures than those who underwent SIC. All patients reported an improved quality of life after their operation. The TDAP group showed significantly more improvement than the SIC group ( P < 0.001). Patients receiving TDAP flaps reported a significant reduction in pain and discomfort and better shoulder function compared with patients in the SIC group ( P < 0.001)., Conclusions: WLE and TDAP flap-based reconstruction for axillary stage 3 HS provide optimal postprocedural functional results with a low complication rate. Complete remission of the disease was observed after the procedure. Despite the relatively slow learning curve of this procedure, the authors strongly recommend this technique as a very good option for the management of stage 3 axillary HS., Clinical Question/level of Evidence: Therapeutic, II., (Copyright © 2023 by the American Society of Plastic Surgeons.)
- Published
- 2023
- Full Text
- View/download PDF
39. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.
- Author
-
Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, and Prens EP
- Subjects
- Humans, Adalimumab, Quality of Life, Treatment Outcome, Severity of Illness Index, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa surgery, Hidradenitis Suppurativa chemically induced
- Abstract
Background: Adalimumab, the only biologic registered for hidradenitis suppurativa, shows clinical response in up to 60% of patients, leaving many patients in need for other treatment options such as surgery., Objective: To compare the clinical effectiveness of adalimumab combined with surgery vs adalimumab monotherapy in patients with moderate to severe hidradenitis suppurativa., Methods: A pragmatic Randomized Controlled Trial was performed from August 2018 to July 2022. Primary outcome was the difference in mean International Hidradenitis Suppurativa Severity Score System reduction after 12 months of treatment with the difference in mean Dermatology Life Quality Index reduction as a key secondary outcome., Results: Thirty-one patients were included per arm. The mean International Hidradenitis Suppurativa Severity Score System at baseline was 23.9 ± 10.7 in the surgery group and 20.9 ± 16.4, in the monotherapy group. After 12 months of treatment the surgery group had a significantly greater reduction in International Hidradenitis Suppurativa Severity Score System compared with the monotherapy group (-19.1 ± 11.3 vs -7.8 ± 11.8, P < .001). Moreover, the surgery group showed a greater reduction in Dermatology Life Quality Index after treatment compared with the monotherapy group (-8.2 ± 6.2 vs -4 ± 7.7, P = .02)., Limitations: The study follow-up was too short to assess surgical recurrence rates., Discussion: Combining adalimumab with surgery resulted in greater clinical effectiveness and improved quality of life after 12 months in patients with moderate to severe hidradenitis suppurativa., Competing Interests: Conflicts of interest None disclosed., (Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
40. Combined medical and surgical therapy for hidradenitis suppurativa.
- Author
-
Elston DM
- Subjects
- Humans, Recurrence, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2023
- Full Text
- View/download PDF
41. Laser and intense pulsed light in the treatment of hidradenitis suppurativa.
- Author
-
Saunte DML and Jemec GBE
- Subjects
- Humans, Carbon Dioxide, Lasers, Treatment Outcome, Hair Removal, Hidradenitis Suppurativa surgery
- Abstract
Treatment of hidradenitis suppurativa (HS) requires a combination of medical, surgical, and lifestyle interventions. Intense pulsed light (IPL) and lasers have been reported to be useful. The aim of this review is to find the evidence supporting IPL and laser treatment of HS and to provide guidance for the management of specific HS lesions. We searched PubMed and Web of Science for "laser" and "hidradenitis suppurativa" on April 6, 2022. Inclusion criteria were >10 patients, reported follow-up, English language, and human subjects with a diagnosis of HS. A total of 724 articles were screened, but only 17 studies qualified for inclusion (IPL (n = 4), Nd:YAG (n = 6), CO
2 laser (n = 6), and intralesional treatment (n = 2). The majority of the studies had a low (n = 10) or moderate (n = 7) evidence level. Treatment effect was noticed in studies using IPL and Nd:YAG (hair reduction). CO2 laser was used for surgery with a success rate ranging from 70.7% to 96.7%. CO2 laser is useful for surgery of stationary HS lesions, but it is difficult to draw a conclusion on the use of IPL and Nd:YAG (hair reduction) as the studies were too heterogeneous to perform a meta-analysis., Competing Interests: Declaration of Competing Interest Zealand University Hospital is a member of the European Reference Network on Rare and Undiagnosed Skin Disorders and the European Hidradenitis Suppurativa Foundation. DML Saunte received honoraria as a consultant for advisory board meetings by AbbVie, Janssen, Sanofi, Leo Pharma, Novartis, UCB and as a speaker and/or received grants from the following companies: Abbvie, Janssen, Novartis, Sanofi, Jamjoom Pharma and Leo Pharma during the last three years. She is a primary investigator for Moberg. GBE Jemec has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Novartis, Pierre Fabre and UCB for participation on advisory boards, and grants from Abbvie, Astra-Zeneca, Inflarx, Janssen-Cilag, Leo Pharma, Novartis, Regeneron and Sanofi, for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer-Ingelheim, Galderma and MSD. He has also received unrestricted departmental grants from Abbvie, Leo Pharma and Novartis., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
42. Cutaneous Malignancy in Hidradenitis Suppurativa.
- Author
-
Jafry M, Novice T, and Mohammad TF
- Subjects
- Humans, Hidradenitis Suppurativa surgery, Skin Neoplasms surgery
- Published
- 2023
- Full Text
- View/download PDF
43. Importance of a multi-tiered treatment approach for intellectually and developmentally disabled patients with hidradenitis suppurativa.
- Author
-
Nosrati A, Torpey ME, Andriano TM, Benesh G, Babbush KM, Hosgood HD, Campton KL, and Cohen SR
- Subjects
- Humans, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Infliximab therapeutic use, Triamcinolone therapeutic use, Contraceptives, Oral therapeutic use, Male, Female, Child, Adolescent, Adult, Middle Aged, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa surgery, Persons with Mental Disabilities
- Abstract
Hidradenitis suppurativa (HS) is a chronic, debilitating skin condition that is characterized by painful pustules, nodules, abscesses, and sinus tracts. The complicated and fast-evolving treatment of HS consists of a multi-tiered approach that includes, antibacterial, antihormonal, anti-inflammatory, and surgical options. Studies have demonstrated an earlier age of onset and increased prevalence of HS in patients with intellectual and developmental disability (IDD) compared to patients without IDD. To explore the use of an intensive multi-tiered HS management algorithm that requires monthly office visits, monthly intravenous therapy, and several daily treatment modalities in an HS population with IDD, we conducted an IRB-approved retrospective chart review of HS patients treated at the Albert Einstein College of Medicine-Montefiore HS Center (HSC) with diagnoses of concurrent IDD to investigate their demographic and diagnostic characteristics, as well as the spectrum of therapies employed in this cohort. A total of 22 HS patients with concomitant IDD, including trisomy 21, unspecified intellectual disability, autism spectrum disorder, and trisomy 13 were identified. Therapies utilized in this cohort for HS included topical and oral antibiotics, spironolactone, finasteride, oral contraceptive pills, infliximab, adalimumab, isotretinoin, intralesional and intramuscular triamcinolone injections, and excisional surgery. In conclusion, our findings indicate that despite the practical challenges, daily oral antibiotic regimens, anti-androgen combinations, oral retinoids, infliximab, adalimumab, and surgery collectively play important roles in treating HS patients with IDD. Our cases underscore the importance of utilizing the full range of modalities as the HS treatment algorithm continues to evolve., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
44. Treatment of hidradenitis suppurativa using skin re-attachment technique.
- Author
-
Wang S, Li XB, Ma Q, and Yang LJ
- Subjects
- Humans, Skin, Hidradenitis Suppurativa surgery
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
45. Evaluation of Outcomes Following Surgical Treatment of Hidradenitis Suppurativa.
- Author
-
Romanowski KS, Galet C, Torres M, and Wibbenmeyer L
- Subjects
- Adult, Humans, Female, Quality of Life, Obesity, Skin Transplantation, Severity of Illness Index, Hidradenitis Suppurativa surgery, Burns surgery
- Abstract
Hidradenitis suppurativa (HS), a chronic disease of the apocrine bearing skin causing induration, pain, draining sinuses, and subcutaneous abscesses, significantly impairs patients' quality of life (QOL). Full-thickness excision followed by skin grafting of the involved area can be curative. Herein, we evaluated the impact of this surgical treatment on QOL and depression symptomatology. Adult patients (≥18 years) who consented to participate filled out the dermatology quality of life (DLQI) and the Patient History Questionnaire (PHQ-9) at consent and at 1, 6, and 12 months post-initial evaluation and surgery. Demographics, HS, admission, and operative information were collected. Sixteen patients were included. Subjects were mainly white (81.3 %) and female (56.3%) with a median age of 38.2 (Interquartile range: 34.2-54.5); 62.5% were obese (BMI= 39.7 [28.4-50.6]). Half of the subjects presented with HS in 2 or more areas. Six patients were still undergoing surgeries at 6 months. One-, six-, and 12-month follow-up surveys were obtained from 14, 11, and 8 subjects for DQLI and from 14, 9, and 5 subjects for PHQ9. DLQI scores significantly decreased at 6 months compared to baseline, which indicates QOL improvement (10 [4-20] vs 15.5 [12-21.8], P = .036). Although not significant, PHQ9 scores tended to decrease. For those with the worst disease, DLQI significantly decreased at both 6 (P = .049) and 12 months (P = .047) compared to baseline. Despite a small sample size, our data suggest that aggressive surgical treatment improves the QOL of HS patients. Further studies are warranted to confirm our findings., (© The Author(s) 2022. Published by Oxford University Press on behalf of the American Burn Association. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
46. Retrospective study of keloid formation after CO 2 excision therapy for hidradenitis suppurativa.
- Author
-
Ezekwe N, Neelam R, Jones BA, Ozog DM, and Hamzavi IH
- Subjects
- Humans, Retrospective Studies, Carbon Dioxide, Hidradenitis Suppurativa surgery, Keloid etiology, Keloid surgery
- Abstract
Competing Interests: Conflicts of interest None disclosed.
- Published
- 2023
- Full Text
- View/download PDF
47. Efficacy of procedural treatments for pediatric hidradenitis suppurativa: A systematic review.
- Author
-
Masson R, Parvathala N, Ma E, Shih T, Atluri S, Sayed CJ, Hogeling M, Shi VY, and Hsiao JL
- Subjects
- Humans, Child, Treatment Outcome, Hidradenitis Suppurativa surgery, Dermatitis
- Abstract
Hidradenitis suppurativa (HS) is a painful, inflammatory skin disease that has historically been understudied in the pediatric population. Procedural interventions, such as surgical excisions, skin grafts, and lasers, are important for comprehensive HS disease management. However, there is a lack of data on procedural treatments for HS in pediatric patients. The purpose of this study was to conduct a systematic review of the literature on the efficacy and safety of procedural treatments for HS in pediatric patients. In April 2022, MEDLINE and EMBASE databases were searched for articles on the efficacy of procedural treatments for HS in patients <18 years of age. Two independent reviewers extracted data from relevant studies. From 1974 to 2021, 23 articles with 81 patients were identified. Patients' Hurley stages included stage I (9.1%, 1/11), II (36.4%, 4/11), and III (54.5%, 6/11). The most extensively studied procedural interventions include negative pressure wound therapy (n = 30), surgical excision with skin graft/flap (n = 19), and endoscopic electrode or laser treatment (n = 11). In all, promising response rates for procedural management strategies were observed in the literature but the findings were largely based on case reports/series. Randomized controlled trials (RCTs), especially those geared toward minimally invasive procedural treatments, are needed to help guide clinicians on the most efficacious treatment modalities for pediatric patients with HS., (© 2023 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
48. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
- Author
-
Tchernev G
- Subjects
- Humans, Middle Aged, Adalimumab therapeutic use, Quality of Life, Anti-Bacterial Agents therapeutic use, Colchicine therapeutic use, Zinc, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa surgery
- Abstract
The loss of efficacy of adalimumab, one of the most commonly used biologics for the treatment of hidradenitis suppurativa/acne inversa, is not news to the scientific community, and it should be noted that the number of cases not responding to this agent has been progressively increasing in recent years. We present a 45-year-old patient with hidradenitis suppurativa/acne inversa (Hurley II-III) with a complaint duration of 3 years who has been on adalimumab 40 mg weekly for 9 months. The lack of improvement in the clinical condition as well as the progression of the disease within the ongoing biologic therapy led to the need for repeated hospitalizations and the additional introduction of intravenous treatment with a regimen of antibiotics (Ertapenem, Metronizadol, Ceftriaxone), zinc, colchicine, and pain relievers. During these hospitalizations, a partial improvement was found, which was not durable and required the parallel administration of antibiotics, colchicine and zinc in combination with adalimumab in an outpatient regimen. Several attempts at surgical treatment/incision in non-specialized units were also made, and these too remained generally unsuccessful or with a nondurable, unsatisfactory clinical outcome. Due to the subsequent consecutive worsening of the symptomatology, the patient was admitted for evaluation of the clinical condition and optimization of treatment. Surgical treatment was performed by surgical deroofing under general anaesthesia, concurrent with discontinuation of adalimumab/antibiotic application and long-term remission was achieved. Surgical deroofing has also been shown to be an effective therapeutic option in the loss/lack of efficacy of adalimumab in patients with hidradenitis suppurativa (Hurley II-III). In the case of therapeutic resistance or worsening of symptomatology in patients with acne inversa within adalimumab therapy, other advanced alternatives such as golimumab, anakinra, etanercept are available. The efficacy of these second-line agents is also questionable due to the development of resistance to them as well, which in turn necessitates the frequent switch to third-line agents such as: Ustekinumab, Tildarkizumab, Certolizumab or Ixekizumab. The future will show to what extent this "trust" could be justified and whether in practice the surgical approach will once again displace the so-called "modern options" as the reasonable next basic and reliable alternative. The disadvantage of modern biological therapy is mainly due to the loss of efficacy/development of resistance over time, multiple side effects and frequent recurrence after discontinuation of treatment. In contrast, in the case of specific, stage-oriented, specialized surgical treatment of hidradenitis suppurativa/ acne inversa, in the form of surgical deroofing, for example, the results are long-lasting and in the case of recurrences: the latter are much more easily managed by dermatosurgery/surgery again. The effect achieved after this type of manipulation is essential for the patients' quality of life and guarantees to a large extent also prevention of the development of keratinocyte tumours in the areas affected by chronic inflammation. Precisely because of the aforementioned facts, in a serious number of patients this type of treatment could be considered as a priority. The rethinking of the guideline and the staging of surgical modalities as first-line therapy could, in a serious number of patients, have a positive effect. Swap for surgery seems to be a good alternative.
- Published
- 2023
49. Wide Excision in Hidradenitis Suppurativa. Does it Modify the Course of Disease?
- Author
-
Butrón-Bris B, Lladó I, Gallo E, Navarro R, Rodríguez-Jiménez P, and Delgado-Jiménez Y
- Subjects
- Humans, Hidradenitis Suppurativa surgery, Fistula surgery
- Abstract
There is a lack of studies assessing whether wide excision surgery in hidradenitis suppurativa affected areas is useful for the global control of the hidradenitis suppurativa. We aimed to find whether surgery results were a better global control on the disease activity in both, the area where the surgery is performed and distant areas. We evaluated the disease course of 17 patients with hidradenitis suppurativa who underwent wide excision of complex fistula tracts between October 2018 and January 2022 at the Hospital Universitario de la Princesa, Madrid. We found that wide excision of complex fistulas produces an overall positive effect on the inflammatory activity in hidradenitis suppurativa that may be important to achieve an adequate control of the disease., (Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
50. Treatment of severe hidradenitis suppurativa with a combination of 5-aminolevulinic acid photodynamic therapy, surgery, and secukinumab.
- Author
-
Fu Z, Wu Q, Bu W, and Xiao D
- Subjects
- Humans, Aminolevulinic Acid therapeutic use, Photosensitizing Agents therapeutic use, Photochemotherapy methods, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa surgery
- Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by nodules, abscesses, fistulas, sinus tracts, and scars, typically in intertriginous areas (Sabat et al., 2022). Therapeutic options include medications, surgical interventions, and physiotherapy; however, clinical management is challenging. We report a case of HS that was refractory to multiple treatments and achieved complete remission with a combination therapy of surgery, 5-aminolevulinic acid photodynamic therapy (ALA-PDT), and secukinumab., Competing Interests: Declaration of Competing Interest None declared., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.